Cyclacel Pharmaceuticals Q1 EPS $(0.42) Beats $(0.68) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.68) by 38.24 percent. This is a 16 percent increase over losses of $(0.50) per share

byBill Haddad

May 11, 2022

1 minute read

Barclays Maintains Equal-Weight on Icon, Lowers Price Target to $215

By Benzinga Newsdesk

Today, 11:05 PM

Barclays analyst Luke Sergott maintains Icon (NASDAQ:ICLR) with a Equal-Weight and lowers the price target from $240 to $215.

ICLR

EV Maker Volta Trucks Raises $43.5M In Series B Funding, Announces 2,500 Pre-Orders

By Chris Katje

Today, 11:05 PM

Volta Trucks, a leading electric truck company, announced receiving new funding and shared an update on order numbers Thursday morning. What Happened: The Swedish electric vehicle company said it had raised EUR 37 million ($43.58 million) in a Series B funding round.

PTRA

Raymond James Maintains Strong Buy on Valero Energy, Raises Price Target to $150

By Benzinga Newsdesk

Today, 11:05 PM

Raymond James analyst Justin Jenkins maintains Valero Energy (NYSE:VLO) with a Strong Buy and raises the price target from $125 to $150.

VLO

Axon Enterprise Q2 EPS $0.38 Beats $0.22 Estimate, Sales $156.43M Miss $175.15M Estimate

By Benzinga Newsdesk

Today, 11:05 PM

Axon Enterprise (NASDAQ:AXON) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.22 by 72.73 percent. This is a 3900 percent increase over losses of $(0.01) per share from the

AXON

Cyclacel Pharmaceuticals Q1 EPS $(0.42) Beats $(0.68) Estimate

Related Posts

Barclays Maintains Equal-Weight on Icon, Lowers Price Target to $215

EV Maker Volta Trucks Raises $43.5M In Series B Funding, Announces 2,500 Pre-Orders

Raymond James Maintains Strong Buy on Valero Energy, Raises Price Target to $150

Axon Enterprise Q2 EPS $0.38 Beats $0.22 Estimate, Sales $156.43M Miss $175.15M Estimate